A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.

被引：0
|
作者：
Wang, Jianbo
Campbell, Matthew T.
Shah, Amishi Yogesh
Goswami, Sangeeta
Msaouel, Pavlos
Alhalabi, Omar
Hahn, Andrew Warren
Kovitz, Craig A.
Jana, Bagi Rp
Araujo, John C.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Corn, Paul Gettys
Tannir, Nizar M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS745
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Razak, Albiruni R. A.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)
    Bergmann, L.
    Grimm, M. O.
    Boleti, E. B.
    Panic, A.
    Gruellich, C.
    Bedke, J.
    Ahrens, M.
    Lorch, A.
    Negrier, S.
    Ravaud, A.
    Retz, M.
    Boegemann, M.
    Ivanyi, P.
    Siemer, S.
    Bathelemy, P.
    Rottey, S.
    Maroto, P.
    Oosting, S.
    Hartmann, A.
    Escudier, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 285 - 285
  • [33] A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
    Ahrens, Marit
    Escudier, Bernard
    Haanen, John B. A. G.
    Boleti, Ekaterini
    Goupil, Marine Gross
    Grimm, Marc-Oliver
    Negrier, Sylvie
    Barthelemy, Philippe
    Gravis, Gwenaelle
    Ivanyi, Philipp
    Bedke, Jens
    Castellano, Daniel
    Panic, Andrej
    Mellado, Begona
    Maroto-Rey, Pablo
    Rottey, Sylvie
    Zschaebitz, Stefanie
    Deckbar, Dorothee
    Hartmann, Arndt
    Bergmann, Lothar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus Nivolumab
    Pham, Felix
    Belkaid, Samy
    Maillet, Denis
    Confavreux, Cyrille B.
    Dalle, Stephane
    Peron, Julien
    BIOMEDICINES, 2022, 10 (11)
  • [35] Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
    Takayama, Koichiro
    Numakura, Kazuyuki
    Igarashi, Ryoma
    Habuchi, Tomonori
    IJU CASE REPORTS, 2022, 5 (06) : 517 - 520
  • [36] Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
    Nakagawa, Takashi
    Kijima, Toshiki
    Imasato, Naoki
    Nagoshi, Akihiko
    Nakamura, Gaku
    Uematsu, Toshitaka
    Suzuki, Issei
    Nishihara, Daisaku
    Kamai, Takao
    IJU CASE REPORTS, 2022, 5 (04) : 293 - 296
  • [37] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [38] Re: Phase II Trial of Cabozantinib Plus Nivolumab in Patients with Non-clear-cell Renal Cell Carcinoma and Genomic Correlates
    Xu, Yunze
    Huang, Yiran
    Zhang, Jin
    EUROPEAN UROLOGY, 2022, 82 (03) : 331 - 332
  • [39] Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
    Choueiri, T. K.
    Powles, T. B.
    Albiges, L.
    Burotto, M.
    Szczylik, C.
    Zurawski, B.
    Riuz, E. Yanez
    Maruzzo, M.
    Zaizar, A. Suarez
    Fein, L. E.
    Schutz, F. A. Barros
    Heng, D. Y. C.
    Wang, F.
    Mataveli, F.
    Chang, Y. L.
    van Kooten Losio, M.
    Rodriguez, C. Suarez
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1431
  • [40] Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
    McKay, Rana R.
    McGregor, Bradley A.
    Xie, Wanling
    Braun, David A.
    Wei, Xiao
    Kyriakopoulos, Christos E.
    Zakharia, Yousef
    Maughan, Benjamin L.
    Rose, Tracy L.
    Stadler, Walter M.
    McDermott, David F.
    Harshman, Lauren C.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (36) : 4240 - +
12345